An in silico Model of T Cell Infiltration Dynamics Based on an Advanced in vitro System to Enhance Preclinical Decision Making in Cancer Immunotherapy

被引:10
|
作者
Lewin, Thomas D. [1 ]
Avignon, Blandine [1 ]
Tovaglieri, Alessio [1 ]
Cabon, Lauriane [1 ]
Gjorevski, Nikolche [1 ]
Hutchinson, Lucy G. [1 ]
机构
[1] Roche Innovat Ctr, Roche Pharm Res & Early Dev, Basel, Switzerland
关键词
cancer immunotherapy; T cell infiltration; in vitro cell systems; mathematical modelling; spatio-temporal analysis; EFFICIENT GLOBAL OPTIMIZATION; HYBRID MATHEMATICAL-MODEL; MIGRATION; DESIGN;
D O I
10.3389/fphar.2022.837261
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cancer immunotherapy often involves the use of engineered molecules to selectively bind and activate T cells located within tumour tissue. Fundamental to the success of such treatments is the presence or recruitment of T cells localised within the tumour microenvironment. Advanced organ-on-a-chip systems provide an in vitro setting in which to investigate how novel molecules influence the spatiotemporal dynamics of T cell infiltration into tissue, both in the context of anti-tumour efficacy and off-tumour toxicity. While highly promising, the complexity of these systems is such that mathematical modelling plays a crucial role in the quantitative evaluation of experimental results and maximising the mechanistic insight derived. We develop a mechanistic, mathematical model of a novel microphysiological in vitro platform that recapitulates T cell infiltration into epithelial tissue, which may be normal or transformed. The mathematical model describes the spatiotemporal dynamics of infiltrating T cells in response to chemotactic cytokine signalling. We integrate the model with dynamic imaging data to optimise key model parameters. The mathematical model demonstrates a good fit to the observed experimental data and accurately describes the distribution of infiltrating T cells. This model is designed to complement the in vitro system; with the potential to elucidate complex biological mechanisms, including the mode of action of novel therapies and the drivers of safety events, and, ultimately, improve the efficacy-safety profile of T cell-targeted cancer immunotherapies.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] CT-EVALUATION OF THE FIRST EIGHTEEN PATIENTS WITH ADVANCED UROTHELIAL URINARY BLADDER CANCER SCHEDULED TO UNDERGO T-CELL BASED ADOPTIVE IMMUNOTHERAPY
    Sherif, A. M.
    Radecka, E.
    Hasan, M. N.
    Shabo, S.
    Marits, P.
    Karlsson, M.
    Thoern, M.
    Schumacher, M. C.
    Winqvist, O.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 210 - 210
  • [32] Preclinical characterization of a PD-1-CD28 fusion receptor in CD4+T cells for T cell-based immunotherapy of pancreatic cancer and Non-Hodgkin Lymphoma
    Rataj, F.
    Kraus, F.
    Grassmann, S.
    Chaloupka, Michael
    Ogonek, Justyna
    Zhang, Jin
    Rausch, Svenja
    Endres, Stefan
    Kobold, Sebastian
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S4 - S4
  • [33] A fully human tissue-based ex vivo cell migration analysis model to study T-cell infiltration and distribution in colorectal cancer liver metastases
    Berthel, Anna
    Suarez-Carmona, Meggy
    Kather, Jakob N.
    Rojas-Moraleda, Rodrigo
    Chaorentong, Pornpimol
    Valous, Nektarios A.
    Klupp, Fee
    Schneider, Martin
    Ulrich, Alexis
    Buechler, Markus
    Zoernig, Inka
    Jaeger, Dirk
    Halama, Niels
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [34] Social network trust relationship environment based advanced ovarian cancer treatment decision-making model: An approach based on linguistic information with experts' multiple confidence levels
    Mandal, Prasenjit
    Samanta, Sovan
    Pal, Madhumandal
    Ranadive, Abhay Sharad Chandra
    EXPERT SYSTEMS WITH APPLICATIONS, 2023, 229
  • [35] Bispecific T-cell engager (BiTE) immunotherapy of ovarian cancer based on MIL-88A MOF/MC gene delivery system
    Zhao, Jing
    Lu, Danping
    Moya, Sergio
    Yan, Haoying
    Qiu, Miaojuan
    Chen, JunZong
    Wang, Xincheng
    Li, Yang
    Pan, Haobo
    Chen, Guochuang
    Wang, Guocheng
    APPLIED MATERIALS TODAY, 2020, 20
  • [36] Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS)
    Zhao, Y.
    Qiao, G.
    Wang, X.
    Song, Y.
    Zhou, X.
    Jiang, N.
    Zhou, L.
    Huang, H.
    Zhao, J.
    Morse, M. A.
    Hobeika, A.
    Ren, J.
    Lyerly, H. K.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (06): : 721 - 728
  • [37] Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients’ preference-based study (PPPS)
    Y. Zhao
    G. Qiao
    X. Wang
    Y. Song
    X. Zhou
    N. Jiang
    L. Zhou
    H. Huang
    J. Zhao
    M. A. Morse
    A. Hobeika
    J. Ren
    H. K. Lyerly
    Clinical and Translational Oncology, 2019, 21 : 721 - 728
  • [38] Machine learning model using 18F-FDG PET/CT-based biomarkers to support clinical decision making in advanced chemorefractory metastatic colorectal cancer
    Dhont, J.
    Levillain, H.
    Guiot, T.
    Vanderlinden, B.
    Boni, K. Brou
    Flamen, P.
    Hendlisz, A.
    Reynaert, N.
    Woff, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S242 - S243
  • [39] A Convolutional Neural Network-Based Intelligent Medical System with Sensors for Assistive Diagnosis and Decision-Making in Non-Small Cell Lung Cancer
    Zhan, Xiangbing
    Long, Huiyun
    Gou, Fangfang
    Duan, Xun
    Kong, Guangqian
    Wu, Jia
    SENSORS, 2021, 21 (23)
  • [40] Feasibility of T-Cell-Based Adoptive Immunotherapy in the First 12 Patients with Advanced Urothelial Urinary Bladder Cancer. Preliminary Data on a New Immunologic Treatment Based on the Sentinel Node Concept
    Sherif, Amir
    Hasan, Mudhar N.
    Marits, Per
    Karlsson, Mona
    Winqvist, Ola
    Thorn, Magnus
    EUROPEAN UROLOGY, 2010, 58 (01) : 105 - 111